SCAI: Ixmyelocel-T studied for dilated cardiomyopathy

May 15, 2012
SCAI: ixmyelocel-T studied for dilated cardiomyopathy

(HealthDay) -- For patients with dilated cardiomyopathy, treatment with an autologous bone marrow-derived, expanded multi-cell product, ixmyelocel-T, is well tolerated and associated with improved symptoms at one year, according to a study presented at the Society for Cardiovascular Angiography and Interventions 2012 Scientific Sessions, held from May 9 to 12 in Las Vegas.

Timothy Henry, M.D., from the Minneapolis Heart Institute Foundation at Abbot Northwestern Hospital in Minnesota, and colleagues conducted a phase 2a trial to assess the safety and preliminary efficacy of intramyocardial delivery of ixmyelocel-T in 22 patients with ischemic and non-ischemic dilated cardiomyopathy. Participants with New York Heart Association (NYHA) Class III/IV, a of 30 percent, and limited treatment options were randomly allocated in a 2:1 ratio to ixmyelocel-T or control. were cultured to expand the number of activated macrophages and and then injected into the after cardiac mapping. Safety and efficacy were assessed at baseline and at three, six, and 12 months.

The researchers found that there were no procedural complications and no between-group differences in adverse events. Improved clinical outcomes were seen in patients with ischemic dilated cardiomyopathy, with a mean number of 0.22 major adverse cardiovascular events, versus 1.67 in control patients. Compared with controls or patients with non-ischemic dilated cardiomyopathy, more patients with ischemic dilated cardiomyopathy had improvements in NYHA Class, six-minute walk distance, and ejection fraction.

"Treatment with ixmyelocel-T was well tolerated and patients who received the cell therapy showed improved symptoms after one year," Henry said in a statement. "The results provide a strong basis for a larger clinical trial of this treatment in patients with dilated cardiomyopathy."

Several authors disclosed financial ties to biotechnology companies, including Aastrom Biosciences, which funded the study.

Explore further: Genetic causes found in nearly 1 in 5 patients with dilated cardiomyopathy heart failure

More information: Press Release
More Information

Related Stories

Genetic causes found in nearly 1 in 5 patients with dilated cardiomyopathy heart failure

March 27, 2012
(Medical Xpress) -- Researchers have identified genetic causes in nearly 1 in 5 patients who suffer a type of heart failure called dilated cardiomyopathy.

Study finds important risk factors for death/transplantation in children with heart muscle disease

July 25, 2011
Researchers have identified important risk factors for death and transplantation in children with dilated cardiomyopathy (heart muscle disease), according to results from a study supported by the National Heart, Lung, and ...

Cell therapy using patient's own bone marrow may present option for heart disease

March 24, 2012
Cell therapy may present an option for patients with ischemic heart disease to use their own bone marrow cells to repair the damaged areas of their hearts, and may pave the way for future treatment options, according to the ...

Hypothermia remains effective in cardiac arrest patients with preexisting cardiomyopathy

November 14, 2011
Cardiomyopathy is common among cardiac arrest survivors. The survival and neuroprotective benefits of therapeutic hypothermia is similar in patients with preexisting cardiomyopathy, compared with those patients without cardiomyopathy, ...

Recommended for you

Majority of U.S. adults have poor heart health: study

March 19, 2018
(HealthDay)—America's heart health went from bad to worse between 1988 and 2014, a new report warns.

Drinking alcohol makes your heart race

March 18, 2018
The more alcohol you drink, the higher your heart rate gets, according to research presented today at EHRA 2018 Congress, organized by the European Society of Cardiology.

Study of nearly 300,000 people challenges the 'obesity paradox'

March 15, 2018
The idea that it might be possible to be overweight or obese but not at increased risk of heart disease, otherwise known as the "obesity paradox", has been challenged by a study of nearly 300,000 people published in in the ...

Mending broken hearts with cardiomyocyte molds

March 13, 2018
2.5 billion. That's approximately the number of times the human heart beats in 70 years. And sometimes during the course of its unrelenting contractions and relaxations, the heart muscle can no longer bear the strain.

Common infections a bigger heart disease and stroke risk than obesity

March 13, 2018
A major study into the impact of common infections leading to hospitalisation has found they may substantially increase the risk of heart attacks, strokes and in the longer term, death.

Aspirin prevents venous thromboembolism following major orthopedic surgeries, study finds

March 13, 2018
A multicentre, double-blind, randomized, controlled clinical trial of patients who underwent total hip or knee replacement surgery showed that aspirin was as effective as rivaroxaban, the standard anti-coagulation medication, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.